Renal Cell Carcinoma

Cabometyx Approved as First-Line Tx for Advanced Renal Cell Carcinoma

By December 20, 2017

Approval provides for treatment in the first-line setting.

Sutent Approved for Patients at High Risk of Recurrent RCC

By November 17, 2017

Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.